Literature DB >> 3605668

Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium.

R R Bartkowski.   

Abstract

Three clinically used anticholinesterases--neostigmine, pyridostigmine, and edrophonium--were tested for their ability to reverse two levels (60% and 95%) of neuromuscular blockade produced by pancuronium. A controlled in vitro environment of the rat diaphragm-phrenic nerve system was used for the studies. Concentrations of anticholinesterases spanned the clinical range and were extended beyond to establish dose-response curves. Neostigmine was the most potent reversal drug (ED50 for 95% block 5.5 +/- 4 nM), followed by pyridostigmine (0.27 +/- 0.06 microM) and edrophonium (2.1 +/- 0.05 microM). The three drugs were equally effective at reversal of block and fade as measured by train-of-four stimulation. The dose-response curves for all three drugs showed a ceiling effect for reversal of tension and fade. Supraclinical concentrations of drug did not effect complete reversal, especially at 95% block. High concentrations of anticholinesterase led to randomly appearing hyperactivity manifested by spontaneous twitching and repetitive firing with severe fade on stimulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3605668

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade.

Authors:  H Kirkegaard-Nielsen; H S Helbo-Hansen; P Lindholm; I K Severinsen; H S Pedersen; E W Jensen
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

Review 2.  Sugammadex: A Review of Neuromuscular Blockade Reversal.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

3.  Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children.

Authors:  J C Bevan; J P Purday; E J Reimer; D R Bevan
Journal:  Can J Anaesth       Date:  1994-11       Impact factor: 5.063

4.  Sugammadex allows fast-track bariatric surgery.

Authors:  Michele Carron; Stefano Veronese; Mirto Foletto; Carlo Ori
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

Review 5.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

6.  The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact.

Authors:  Edoardo De Robertis; Geremia Zito Marinosci; Giovanni Marco Romano; Ornella Piazza; Michele Iannuzzi; Fabrizio Cirillo; Stefania De Simone; Giuseppe Servillo
Journal:  Clinicoecon Outcomes Res       Date:  2016-06-29

7.  Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey.

Authors:  Jin Sun Kim; Jung Woo Han; Jae Ho Lee; Jae Moon Choi; Ha Jung Kim; Tae-Yun Sung; Yong Beom Kim; Yong Seop Shin; Hong Seuk Yang
Journal:  Anesth Pain Med (Seoul)       Date:  2019-10-31

8.  Efficacy and Safety of Sugammadex versus Neostigmine in Reversing Neuromuscular Blockade in Morbidly Obese Adult Patients: A Systematic Review and Meta-Analysis.

Authors:  Yamini Subramani; Jill Querney; Susan He; Mahesh Nagappa; Homer Yang; Ashraf Fayad
Journal:  Anesth Essays Res       Date:  2021-08-30

9.  Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases.

Authors:  Tomas Vymazal; Martina Krecmerova; Vladimír Bicek; Robert Lischke
Journal:  Ther Clin Risk Manag       Date:  2015-10-15       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.